Enlivex Therapeutics Ltd. ENLV

$ 1.25 5.81%

Annual report 2023
added 12-21-2024

Enlivex Therapeutics Ltd. Income Statement 2011-2024 | ENLV

Annual Income Statement Enlivex Therapeutics Ltd.

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	28.2 M	46.2 M	112 M	123 M	72.6 M	21.7 M	62.7 M	16.6 M	52.1 M	99.9 M	-	-	-
Shares	18.6 M	18.4 M	17.9 M	14.6 M	8.65 M	3.51 M	3.43 M	399 K	356 K	306 K	-	-	-
Historical Prices	1.52	2.51	6.25	8.43	8.39	6.19	18.3	41.6	155	256	-	-	-
Net Income	-29.1 M	-31.1 M	-14.5 M	-11.8 M	-9.38 M	-4.24 M	-2.5 M	-16 M	-15.4 M	-7.02 M	-1.14 M	-229 K	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	737 K	569 K	525 K	365 K	373 K	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-29.4 M	-25.8 M	-19.3 M	-9.78 M	-8.62 M	-5.3 M	-2.17 M	-15.9 M	-15.5 M	-7.08 M	-1.15 M	-226 K	-
Interest Expense	327 K	-5.26 M	4.82 M	-2.04 M	-765 K	-4 K	38 K	60 K	-	-	-	-	-
EBITDA	-	-	-18.7 M	-9.5 M	-8.41 M	-5.18 M	-2.09 M	-15.8 M	-15.5 M	-7.08 M	-1.14 M	-226 K	-
Operating Expenses	-	-	19.3 M	-	8.62 M	5.3 M	5.96 M	15.9 M	15.5 M	7.08 M	-	-	-
General and Administrative Expenses	471 K	707 K	367 K	3.7 M	3.02 M	96 K	16 K	5.9 M	6.95 M	2.64 M	416 K	-	-

All numbers in USD currency

Quarterly Income Statement Enlivex Therapeutics Ltd.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	-	-	-	-	18.3 M	-	18.3 M	-	14.6 M	-	13.4 M	-	10.3 M	-	10.1 M	-	3.51 M	-	-	-	418 K	-	-	-	3.28 M	-	-	-	14.2 M	-	-	-	14.2 M	-	-	-	9.18 M	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-3.11 M	-	-	-	-3.04 M	-	-	-	-1.46 M	-	-	-	-	-	-	-	-	-	-3.07 M	-4.67 M	-3.68 M	-4.59 M	-4.83 M	-3.55 M	-3.69 M	-3.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-	-	-	-	-3.81 M	-	-	-	-2.23 M	-	-	-	-1.3 M	-	-	-	-	-	-	-	-	-	-3.07 M	-4.58 M	-3.72 M	-4.49 M	-4.83 M	-3.59 M	-3.74 M	-3.32 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	700 K	-	-	-	-808 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-3.69 M	-	-	-	-2.17 M	-	-	-	-1.2 M	-	-	-	-	-	-	-	-	-	-3.07 M	-4.58 M	-3.72 M	-4.49 M	-4.83 M	-3.59 M	-3.74 M	-3.32 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	3.81 M	-	-	-	2.23 M	-	-	-	1.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	-	-	-	-	-	-	1.27 M	-	-	-	976 K	-	-	-	601 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency